A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

NCT01846832 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic
Infection

Interventions

DRUG: TMC435
DRUG: Pegylated interferon alfa-2a (PegIFNα-2a)
DRUG: Ribavirin (RBV)

Sponsor

Janssen-Cilag International NV